公开(公告)号：US20170166974A1

公开(公告)日：2017-06-15

申请号：US15312544

申请日：2014-05-20

申请人： Erasmus University Medical CEnter Rotherdam

发明人： Annemiek Broijl ,  Pieter Sonneveld ,  Martinus Hendrikus Van Vliet

IPC分类号： C12Q1/68 ,  A61K38/05

CPC分类号： C12Q1/6886 ,  A61K38/05 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： The disclosure is in the field of medical treatments and relates to the treatment of multiple myeloma (MM). In particular, it provides means and methods for the improved treatment of certain subgroups of MM patients, more in particular, patients with a poor prognosis. In a particular embodiment, the disclosure provides a method for determining whether a subject with multiple myeloma is likely to respond to a treatment with a proteasome inhibitor wherein the method comprises the step of performing, on a sample from the subject, a gene expression analysis of a number of N genes selected from the group consisting of the genes NUAK1, ITGB7, AGMAT, TFAP2C, CCDC85A, CLEC7A, TMEM37, RNF144A, and CMPK2, wherein N is at least 2 and wherein it is concluded that the subject is likely to respond to a treatment with a proteasome inhibitor in the case where at least two of the N genes are aberrantly expressed.